Extensively drug-resistant Shigella infections are rising globally, with significant increases reported in both children and adults.
Recent CDC and global studies show most cases resist all commonly used antibiotics, complicating treatment and raising public health concerns.
Experts warn of limited treatment options, urge vaccine development, and highlight the risk of further spread due to high transmissibility.
How will global health systems address XDR Shigella's dual impact on children and adult men?
Will XDR Shigella's spread force a radical shift in global antibiotic stewardship?
How are public health campaigns adapting to Shigella's increasing sexual transmission?
What are the hidden economic and ethical costs of rising XDR Shigella globally?
What immediate actions are public health officials taking, following today's CDC report on XDR Shigella?
Beyond vaccines, what novel treatments offer hope for untreatable XDR Shigella infections?
Global Surge of Extensively Drug-Resistant Shigella: Rising Cases, Limited Treatments, and Urgent Vaccine Development (2023–2026)
Overview
From 2023 to 2026, extensively drug-resistant (XDR) Shigella infections have surged globally, with resistance to nearly all first-line antibiotics severely limiting treatment options. This rise is driven by highly efficient transmission, especially sexual contact among gay, bisexual, and other men who have sex with men (GBMSM), and widespread antibiotic misuse in both human medicine and agriculture. Vulnerable groups, including adults with HIV and children in low-resource settings, face the greatest health impacts, such as prolonged illness and hospitalizations. In response, public health agencies have intensified surveillance and prevention efforts, while promising vaccine candidates advance through clinical trials, aiming for licensure by 2028-2030 to provide a long-term solution against this escalating threat.